Tech Company Financing Transactions
Alesta Therapeutics Funding Round
Alesta Therapeutics secured a $67 million Series A funding round on 1/8/2025. Investors included Droia Ventures, Frazier Life Sciences and Novartis Venture Fund.
Transaction Overview
Company Name
Announced On
1/8/2025
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series A
Investors
Droia Ventures (Lead Investor)
Frazier Life Sciences (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D sector.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Leiden, Undisclosed
The Netherlands
Leiden, Undisclosed
The Netherlands
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Alesta Therapeutics, a Leiden, the Netherlands-based biotechnology company focused on developing transformative small molecule therapies for rare diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ilan Ganot
Chief Medical Officer
Benit Maru
Chief Scientific Officer
Matthias Van Woensel
Browse more venture capital transactions:
Prev: 1/8/2025: 360 Advanced venture capital transaction
Next: 1/8/2025: Grove AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. All VC database entries reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs